Cargando…

Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients

Background and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Berar-Yanay, Noa, Freiman, Sarit, Shapira, Maʹanit, Saffoury, Amer, Elemy, Ameer, Hamze, Munir, Elhaj, Mohamad, Zaher, Maha, Matanis, Loai, Armaly, Zaher Anis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745040/
https://www.ncbi.nlm.nih.gov/pubmed/35011801
http://dx.doi.org/10.3390/jcm11010064
_version_ 1784630248896200704
author Berar-Yanay, Noa
Freiman, Sarit
Shapira, Maʹanit
Saffoury, Amer
Elemy, Ameer
Hamze, Munir
Elhaj, Mohamad
Zaher, Maha
Matanis, Loai
Armaly, Zaher Anis
author_facet Berar-Yanay, Noa
Freiman, Sarit
Shapira, Maʹanit
Saffoury, Amer
Elemy, Ameer
Hamze, Munir
Elhaj, Mohamad
Zaher, Maha
Matanis, Loai
Armaly, Zaher Anis
author_sort Berar-Yanay, Noa
collection PubMed
description Background and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibody level in dialysis patients. Design, setting, participants, and measurements: In an observational study, we measured SARS-COV-2 anti-spike antibody levels in dialysis patients who completed 2 doses of the BNT162b2 mRNA SAR S-COV-2 vaccine at 1, 3 and 6 months after the second vaccine dose. We compared the response to dialysis patients who were infected with COVD-19 and to a control group of healthcare-employees. Results: One hundred and forty-two dialysis patients who had been vaccinated (ages 64 ± 11.9 years, 61% male), 33 dialysis patients who had COVID-19 infection (ages 54 ± 14.3 years, 55% male) and 104 individuals in the control group (ages 50 ± 12.2 years, 44% male) were included. The response rate in the vaccinated dialysis patients was 94%, 78% and 73% at 1, 3 and 6 months after the second vaccine dose. In the COVID-19 infected dialysis group and in the control group, the response rate remained at 100% over 6 months. The percentage of change in antibody levels between one and 6 months was −66% in the vaccinated dialysis group, −28% in the control group (p < 0.001) and +48% in dialysis patients who had been infected with COVID-19 (p < 0.001). A non-responder status at 6 months was associated with a lower albumin level. No serious adverse events following vaccination were reported. In conclusion: the initially high response rate to the BNT162b2 vaccine in dialysis patients decreases rapidly. Our results indicate that an early booster (3rd) dose, at three months after the second dose, may be advised for this population to preserve the humoral immunity.
format Online
Article
Text
id pubmed-8745040
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87450402022-01-11 Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients Berar-Yanay, Noa Freiman, Sarit Shapira, Maʹanit Saffoury, Amer Elemy, Ameer Hamze, Munir Elhaj, Mohamad Zaher, Maha Matanis, Loai Armaly, Zaher Anis J Clin Med Article Background and objectives: The short-term reported antibody response to SARS-COV-2 vaccination in dialysis patients is high, with a seroconversion response rate up to 97%. Data on the long-term durability of this response are scarce. Our objective was to characterize the long-term anti-spike antibody level in dialysis patients. Design, setting, participants, and measurements: In an observational study, we measured SARS-COV-2 anti-spike antibody levels in dialysis patients who completed 2 doses of the BNT162b2 mRNA SAR S-COV-2 vaccine at 1, 3 and 6 months after the second vaccine dose. We compared the response to dialysis patients who were infected with COVD-19 and to a control group of healthcare-employees. Results: One hundred and forty-two dialysis patients who had been vaccinated (ages 64 ± 11.9 years, 61% male), 33 dialysis patients who had COVID-19 infection (ages 54 ± 14.3 years, 55% male) and 104 individuals in the control group (ages 50 ± 12.2 years, 44% male) were included. The response rate in the vaccinated dialysis patients was 94%, 78% and 73% at 1, 3 and 6 months after the second vaccine dose. In the COVID-19 infected dialysis group and in the control group, the response rate remained at 100% over 6 months. The percentage of change in antibody levels between one and 6 months was −66% in the vaccinated dialysis group, −28% in the control group (p < 0.001) and +48% in dialysis patients who had been infected with COVID-19 (p < 0.001). A non-responder status at 6 months was associated with a lower albumin level. No serious adverse events following vaccination were reported. In conclusion: the initially high response rate to the BNT162b2 vaccine in dialysis patients decreases rapidly. Our results indicate that an early booster (3rd) dose, at three months after the second dose, may be advised for this population to preserve the humoral immunity. MDPI 2021-12-23 /pmc/articles/PMC8745040/ /pubmed/35011801 http://dx.doi.org/10.3390/jcm11010064 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Berar-Yanay, Noa
Freiman, Sarit
Shapira, Maʹanit
Saffoury, Amer
Elemy, Ameer
Hamze, Munir
Elhaj, Mohamad
Zaher, Maha
Matanis, Loai
Armaly, Zaher Anis
Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
title Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
title_full Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
title_fullStr Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
title_full_unstemmed Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
title_short Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients
title_sort waning humoral response 3 to 6 months after vaccination with the sars-cov-2 bnt162b2 mrna vaccine in dialysis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8745040/
https://www.ncbi.nlm.nih.gov/pubmed/35011801
http://dx.doi.org/10.3390/jcm11010064
work_keys_str_mv AT beraryanaynoa waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients
AT freimansarit waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients
AT shapiramaʹanit waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients
AT saffouryamer waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients
AT elemyameer waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients
AT hamzemunir waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients
AT elhajmohamad waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients
AT zahermaha waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients
AT matanisloai waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients
AT armalyzaheranis waninghumoralresponse3to6monthsaftervaccinationwiththesarscov2bnt162b2mrnavaccineindialysispatients